Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006, 5: 37-50.
CAS
PubMed
Google Scholar
Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H: The role of DNA methylation in setting up chromatin structure during development. Nature Genet. 2003, 34: 187-192.
CAS
PubMed
Google Scholar
Cang S, Liu DL: Clinical advances in hypomethylating agents for epigenetic therapy of cancer. Current Cancer Drug Targets submitted and under review. 2009
Google Scholar
Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene. 2007, 26: 1351-1356.
CAS
PubMed
Google Scholar
Marks PA, Dokmanovic M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005, 14: 1497-1511.
CAS
PubMed
Google Scholar
Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007, 26: 5541-5552.
CAS
PubMed
Google Scholar
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002, 20: 2429-2440.
CAS
PubMed
Google Scholar
Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008, 112: 2341-2351.
CAS
PubMed
Google Scholar
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006, 106: 1794-1803.
CAS
PubMed
Google Scholar
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'brien S, Cortes J: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007, 109: 52-57.
CAS
PubMed
Google Scholar
Dokmanovic M, Marks PA: Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005, 96: 293-304.
CAS
PubMed
Google Scholar
Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB: Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther. 2007, 6: 2525-2534.
CAS
PubMed
Google Scholar
Dokmanovic M, Clarke C, Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007, 5: 981-989.
CAS
PubMed
Google Scholar
Raj K, John A, Ho A, Chronis C, Khan S, Samuel J: CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007, 21: 1937-1944.
CAS
PubMed
Google Scholar
Kelly WK, Richon VM, O'Connor O, Curley T, Gregor-Curtelli B, Tong W: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003, 9: 3578-3588.
CAS
PubMed
Google Scholar
Kelly WK, Marks PA: Drug insight: Histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005, 2: 150-157.
CAS
PubMed
Google Scholar
Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005, 23: 3923-3931.
PubMed Central
CAS
PubMed
Google Scholar
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007, 109: 31-39.
PubMed Central
CAS
PubMed
Google Scholar
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007, 25: 3109-3115.
CAS
PubMed
Google Scholar
Olsen EA, Duvic M, Breneman D, Pacheco TR, Parker S, Vonderheid EC: Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL). J Clin Oncol. 2008, 26:
Google Scholar
Siegel DS, Hussein MA, Belani CP, Robert F, Rizvi S, Wigginton J: Safety and tolerability of vorinostat – Experience from the vorinostat clinical trial program. J Clin Oncol. 2008, 26:
Google Scholar
Vansteenkiste J, Van CE, Dumez H, Chen C, Ricker JL, Randolph SS: Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008, 26: 483-488.
CAS
PubMed
Google Scholar
Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H: Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008, 19: 964-969.
CAS
PubMed
Google Scholar
Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008, 111: 1060-1066.
CAS
PubMed
Google Scholar
Badros AZ, Philip S, Niesvizk R, Goloubeva O, Harris C, Zweibel J: Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts). J Clin Oncol [Proc Am Soc Clin Oncol]. 2008, 26: abst # 8548. Ref Type: Journal (Full)
Google Scholar
Chin K, Hatake K, Hamaguchi T, Shirao K, Doi T, Noguchi K: A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer. J Clin Oncol. 2008, 26:
Google Scholar
Hammers HJ, Verheul H, Wilky B, Salumbides B, Holleran J, Egorin MJ: Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer. J Clin Oncol. 2008, 26:
Google Scholar
Hymes K, Dummer R, Sterry W, Steinhoff M, Assaf C, Kerl H: Phase I trial of oral vorinostat in combination with bexarotene in patients with advanced cutaneous T-cell lymphoma. J Clin Oncol. 2008, 26:
Google Scholar
Fan J, Yin WJ, Lu JS, Wang L, Wu J, Wu FY: ERalpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008, 134: 883-890.
CAS
PubMed
Google Scholar
Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ: The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene. 2004, 23: 1724-1736.
CAS
PubMed
Google Scholar
Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D: A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003, 81: 177-186.
CAS
PubMed
Google Scholar
Munster PN, Lacevic M, Schmitt M, Bicaku E, Marchion D, Stephens A: Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. J Clin Oncol. 2008, 26 (36): 5896-5903.
PubMed Central
PubMed
Google Scholar
Townsley C, Oza AM, Tang P, Siu LL, Pond GR, Sarveswaran P: Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. J Clin Oncol J Clin Oncol. 2008 Mar 10;26(8):1324-30. 2008, 26 (8): 1324-1330.
Google Scholar
Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007, 13: 3605-3610.
CAS
PubMed
Google Scholar
Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J: Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006, 7: 257-261.
PubMed
Google Scholar
Cheung EM, Quinn DI, Tsao-Wei DD, Groshen SG, Aparicio AM, Twardowski P: Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy – California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. J Clin Oncol. 2008, 26:
Google Scholar
Modesitt SC, Sill M, Hoffman JS, Bender DP: A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008, 109: 182-186.
CAS
PubMed
Google Scholar
Misset J, Tredaniel J, Descourt R, Morot-Sibilot D, Zalcman G, Gachard E: Vorinostat in combination with gemcitabine plus platinum in patients with advanced non-small-cell lung cancer: A phase I, dose-escalation study. J Clin Oncol. 2008, 26:
Google Scholar
Fouladi M, Park JR, Sun J, Ingle AM, Ames MM, Stewart CF: A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. J Clin Oncol. 2008, 26:
Google Scholar
Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J: Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008, 49: 502-507.
CAS
PubMed
Google Scholar
Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL: Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008, 26: 81-87.
CAS
PubMed
Google Scholar
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999, 401: 188-193.
CAS
PubMed
Google Scholar
Acharya MR, Sparreboom A, Venitz J, Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol. 2005, 68: 917-932.
CAS
PubMed
Google Scholar
Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5: 769-784.
CAS
PubMed
Google Scholar
Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL: Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther. 2003, 2: 401-408.
CAS
PubMed
Google Scholar
Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L: Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs. 2001, 19: 1-11.
CAS
PubMed
Google Scholar
Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R: Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. 2003, 9: 58-66.
CAS
PubMed
Google Scholar
Pauer LR, Olivares J, Cunningham C, Williams A, Grove W, Kraker A: Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 2004, 22: 886-896.
CAS
PubMed
Google Scholar
Undevia SD, Janisch L, Schilsky RL, Loury D, Balasubramanian S, Mani C: Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J Clin Oncol. 2008, 26:
Google Scholar
Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ: A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004, 15: 1705-1711.
CAS
PubMed
Google Scholar
Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998, 241: 126-133.
CAS
PubMed
Google Scholar
Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994, 47: 301-310.
CAS
Google Scholar
Doss HH, Jones SF, Infante JR, Spigel DR, Willcutt N, Lamar R: A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J Clin Oncol. 2008, 26:
Google Scholar
Piekarz R, Luchenko V, Draper D, Wright JJ, Figg WD, Fojo AT: Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol. 2008, 26:
Google Scholar
Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008, 14: 826-832.
CAS
PubMed
Google Scholar
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF: Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res. 2008, 14: 188-198.
CAS
PubMed
Google Scholar
Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA: A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006, 5: 57-60.
CAS
PubMed
Google Scholar
Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006, 12: 3762-3773.
CAS
PubMed
Google Scholar
Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P: The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005, 11: 1-15.
PubMed Central
CAS
PubMed
Google Scholar
Viviani S, Bonfante V, Fasola C, Valagussa P, Gianni AM: Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients. J Clin Oncol. 2008, 26:
Google Scholar
Galli M, Salmoiraghi S, Golay J, Gozzini A, Bosi A, Crippa C: A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood. 2007, 110 (11):
Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005, 280: 26729-26734.
CAS
PubMed
Google Scholar
Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006, 12: 4628-4635.
CAS
PubMed
Google Scholar
Rathkopf DE, Wong BY, Ross RW, George DJ, Picus J, Tanaka E: A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC). J Clin Oncol J Clin Oncol. 2008 Jun 20;26(18):2959-65. 2008, 26 (18): 2959-2965.
CAS
Google Scholar
Duvic M, Vanaclocha F, Bernengo MG, Okada C, Breneman D, Zinzani PL: Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL). J Clin Oncol. 2008, 26:
Google Scholar
Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F: Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem. 2008, 51: 4072-4075.
CAS
PubMed
Google Scholar
Tourneau CL, Siu LL: Promising antitumor activity with MGCD0103 a novel isotype-selective histone deacetylase inhibitor. Expert Opin Investig Drugs. 2008, 17: 1247-1254.
PubMed
Google Scholar
Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R: Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol. 2008, 26: 1940-1947.
PubMed Central
CAS
PubMed
Google Scholar
Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H: Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008, 112: 981-989.
PubMed Central
CAS
PubMed
Google Scholar
Hurwitz H, Nelson B, O'Dwyer PJ, Chiorean EG, Gabrail N, Laille E: Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. J Clin Oncol. 2008, 26: abst # 4625. Ref Type: Journal (Full)
Google Scholar
Crump M, Andreadis C, Assouline S, Rizzieri D, Wedgwood A, McLaughlin P: Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. J Clin Oncol. 2008, 26:
Google Scholar
Bociek RG, Kuruvilla J, Pro B, Wedgwood A, Li Z, Drouin M: Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). J Clin Oncol. 2008, 26:
Google Scholar
Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T: A synthetic inhibitor of histone deacetylase, MS-27–275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 1999, 96: 4592-4597.
PubMed Central
CAS
PubMed
Google Scholar
Hess-Stumpp H, Bracker TU, Henderson D, Politz O: MS-275, a potent orally available inhibitor of histone deacetylases – the development of an anticancer agent. Int J Biochem Cell Biol. 2007, 39: 1388-1405.
CAS
PubMed
Google Scholar
Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007, 109: 2781-2790.
PubMed Central
CAS
PubMed
Google Scholar
Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D: A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas. Clin Cancer Res. 2008, 14: 4517-4525.
PubMed Central
CAS
PubMed
Google Scholar
Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F: Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-4-{[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res. 2008, 18: 274-278.
CAS
PubMed
Google Scholar
Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L: CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006, 5: 1309-1317.
CAS
PubMed
Google Scholar
Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA: Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001, 61: 1477-1485.
CAS
PubMed
Google Scholar
Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG: Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs. 2007, 25: 131-138.
CAS
PubMed
Google Scholar
Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res. 2001, 7: 3047-3055.
CAS
PubMed
Google Scholar
Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001, 7: 2292-2300.
CAS
PubMed
Google Scholar
Sung MW, Waxman S: Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res. 2007, 27: 995-1001.
CAS
PubMed
Google Scholar
Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I: Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia. 2006, 20: 212-217.
CAS
PubMed
Google Scholar
Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003, 2: 721-728.
CAS
PubMed
Google Scholar
Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A: A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008, 14: 804-810.
CAS
PubMed
Google Scholar
Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE: A Phase I clinical trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with advanced haematological neoplasia. Eur J Haematol. 2008, 81: 170-176.
CAS
PubMed
Google Scholar
Mackay H, Hirte HW, Covens A, MacAlpine K, Wang L, Tsao MS: A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial. J Clin Oncol. 2008, 26:
Google Scholar
Gottlicher M, S Minucci, P Zhu, OH Kramer, A Schimpf, S Giavara: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20: 6969-6978.
PubMed Central
CAS
PubMed
Google Scholar
Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006, 106: 112-119.
CAS
PubMed
Google Scholar
Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K: Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005, 104: 2717-2725.
CAS
PubMed
Google Scholar
Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M: Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer. 2005, 4: 22-
PubMed Central
PubMed
Google Scholar
Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007, 97: 177-182.
PubMed Central
CAS
PubMed
Google Scholar
Shapiro TA, Fahey JW, nkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL: Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer. 2006, 55: 53-62.
CAS
PubMed
Google Scholar
Chiao JW, Wu H, Ramaswamy G, Conaway CC, Chung FL, Wang L: Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis. 2004, 25: 1403-1408.
CAS
PubMed
Google Scholar
Lu L, Liu D, Ma X, Beklemishev A, Seiter K, Ahmed T: The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep. 2006, 16: 1363-1367.
CAS
PubMed
Google Scholar
Lu Q, Lin X, Feng J, Zhao X, Gallagher R, Lee MY: Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol. 2008, 1: 6-
PubMed Central
PubMed
Google Scholar
Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T: Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 2006, 28: 1287-1293.
CAS
PubMed
Google Scholar
Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J, Chiao JW: Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog. 2007, 46: 24-31.
CAS
PubMed
Google Scholar
Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM: De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol. 2008, 33: 375-380.
CAS
PubMed
Google Scholar
Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L: The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004, 64: 6626-6634.
CAS
PubMed
Google Scholar
Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N: N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem. 2003, 46: 4609-4624.
CAS
PubMed
Google Scholar
Hurtubise A, Momparler RL: Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006, 58: 618-625.
CAS
PubMed
Google Scholar
Grant S: The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?. Leukemia. 2004, 18: 1931-1933.
CAS
PubMed
Google Scholar
Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S: Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp. 2004, 259: 249-266.
CAS
PubMed
Google Scholar
Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004, 64: 689-695.
CAS
PubMed
Google Scholar